Clinical Trial Update: E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating an EGFR tyrosine kinase inhibitor in combination with EGF receptor pathway targeting in EGFR-mutant non-small cell lung cancer; trial…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• EGFR TKI in combination with EGF-P TI C Ombination

Snippet

Sponsor: Instituto Oncológico Dr Rosell | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: COMPLETED